H.C. Wainwright analyst Raghuram Selvaraju downgraded Oramed to Neutral from Buy without a price target after the company disclosed that its pivotal clinical trial of the lead oral insulin candidate ORMD-0801 had failed. The analyst now expects Oramed to halt the ORA-D-013-2 pivotal trial, which was slated to enroll 450 patients.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ORMP:
- Oramed down 73% after phase 3 study of ORMD-0801 did not meet primary endpoint
- Oramed downgraded to Hold at Canaccord after ORMD-0801 discontinued
- Oramed downgraded to Hold from Buy at Canaccord
- Oramed Crashes after Disappointing Topline Results
- Oramed’s results from phase 3 trial of ORMD-0801 did not meet primary endpoint
